Clinical Pipeline
Jiuzhitang Maker is dedicated to R&D innovation in stem cell products, leveraging its profound scientific expertise and relentless spirit of exploration to deliver cutting-edge, high-efficiency treatment solutions for the medical field. The company focuses on therapeutic areas such as ischemic stroke, immune-mediated pulmonary alveolar proteinosis, and autism spectrum disorder, actively conducting in-depth research and pioneering innovative applications of stem cells to tackle challenging clinical issues. Currently, Jiuzhitang Maker has successfully advanced three novel stem cell drugs into the clinical trial phase—each representing the first-of-its-kind treatment options, either domestically or even globally—solidifying the company’s undisputed leadership position in China and underscoring its formidable strength in medical innovation.
Traditional medicines often prove powerless when tackling some complex diseases, whereas stem cells have demonstrated remarkable efficacy in a wide range of fields, including diabetes, Parkinson’s syndrome, Alzheimer’s disease, liver fibrosis, and anti-aging treatments. With advancements in science and the gradual refinement of supportive policies, the clinical applications of stem cells are steadily expanding. Looking ahead, stem cells hold immense promise in offering patients new hope for treating a variety of challenging and difficult-to-cure conditions.
Mesenchymal stem cells have already been applied or have entered the clinical trial validation phase for the following diseases:
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy